Our drug candidates have been designed to provide safe single agent efficacy in multiple adjacent indications, as well as enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
View Product PipelineCG-806 is a potent non-covalent inhibitor of wildtype and mutant forms of BTK, as well as multiple oncogenic signaling pathways operative in CLL and other B-cell malignancies.
View CandidateCG-806 potently inhibits wildtype and all mutant forms of FLT3 which are an oncogenic drivers in AML and MDS, as well as other oncogenic rescue pathways operative in myeloid malignancies.
View CandidateAPTO-253 is the first clinical small molecule that directly and selectively targets the MYC oncogene and inhibits the production of MYC mRNA and protein, leading to cell cycle arrest and apoptosis of tumor cells.
View Candidate
Currently, we have three ongoing clinical trials with our investigational drug candidates:
CG-806 is in a Phase 1a/b clinical trial for the treatment of patients with B-cell malignancies, including CLL and NHL, who have failed or are intolerant to the standard treatments available.
CG-806 is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML.
APTO-253 is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML and high risk MDS.
View Clinical Trials